Adicet Bio (ACET) to Release Quarterly Earnings on Thursday

Key Points

• Adicet Bio is set to release its Q2 2025 earnings on August 12, with analysts anticipating a loss of ($0.32) per share.
• The company's stock recently traded at $0.73 with a market cap of $60.05 million and a P/E ratio of -0.56.
• Analysts have various ratings for Adicet Bio, with most rating it a "Moderate Buy"** and a target price averaging $6.00.

Adicet Bio (NASDAQ:ACET - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect Adicet Bio to post earnings of ($0.32) per share for the quarter.

Adicet Bio (NASDAQ:ACET - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.02). On average, analysts expect Adicet Bio to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Adicet Bio Price Performance

Shares of NASDAQ ACET traded down $0.07 during trading hours on Friday, hitting $0.62. 2,370,726 shares of the company's stock were exchanged, compared to its average volume of 305,725. Adicet Bio has a 1-year low of $0.45 and a 1-year high of $1.64. The stock has a market capitalization of $51.36 million, a price-to-earnings ratio of -0.47 and a beta of 1.59. The company's 50-day moving average price is $0.71 and its 200-day moving average price is $0.74.

Institutional Trading of Adicet Bio

An institutional investor recently raised its position in Adicet Bio stock. Goldman Sachs Group Inc. raised its position in Adicet Bio, Inc. (NASDAQ:ACET - Free Report) by 1.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,816,556 shares of the company's stock after purchasing an additional 63,691 shares during the quarter. Goldman Sachs Group Inc. owned 4.61% of Adicet Bio worth $2,882,000 at the end of the most recent reporting period. Institutional investors own 83.89% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on ACET. Wall Street Zen began coverage on Adicet Bio in a report on Friday, May 16th. They issued a "hold" rating for the company. HC Wainwright upgraded Adicet Bio to a "strong-buy" rating and set a $4.00 price objective on the stock in a research note on Wednesday, July 23rd. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Adicet Bio currently has an average rating of "Moderate Buy" and a consensus target price of $6.00.

About Adicet Bio

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.